公开(公告)号：US20150330999A1

公开(公告)日：2015-11-19

申请号：US14811074

申请日：2015-07-28

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Nicholas PAPADOPOULOS ,  Anthony DORE ,  Douglas MACDONALD

IPC: G01N33/74

CPC classification number: G01N33/74 ,  C07K14/71 ,  C07K16/22 ,  C07K2319/30 ,  G01N2333/515 ,  G01N2800/52

Abstract: The invention provides a method for enriching the level of VEGF-A121 isoform in a sample by selectively removing the VEGF-A165 isoform from the sample using a neuropilin-1 pull-down procedure, then determining the total amount of VEGF-A remaining afterward. The invention provides methods of treating a patient suffering from a disease which may benefit from the administration of a VEGF antagonist by determining the level or ratio of VEGF-A121 in the patient's circulation. Methods of diagnosis, prognosis, monitoring, and patient stratification are also provided.

公开(公告)号：US20130064834A1

公开(公告)日：2013-03-14

申请号：US13672792

申请日：2012-11-09

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Mark W. SLEEMAN ,  Joel H. MARTIN ,  Tammy T. HUANG ,  Douglas MACDONALD ,  Gary SWERGOLD ,  Robert C. PORDY ,  William J. SASIELA

IPC: A61K39/395 ,  A61P3/00

CPC classification number: A61K39/3955 ,  A61K31/40 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

Abstract: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.

Abstract translation: 本发明提供治疗高胆固醇血症的方法。 本发明的方法包括向有需要的受试者施用包含抗PCSK9抗体或其抗原结合片段的治疗组合物。

公开(公告)号：US20170096496A1

公开(公告)日：2017-04-06

申请号：US15377364

申请日：2016-12-13

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Mark W. SLEEMAN ,  Joel H. MARTIN ,  Tammy T. HUANG ,  Douglas MACDONALD

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12Y304/21061

Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

公开(公告)号：US20150330998A1

公开(公告)日：2015-11-19

申请号：US14811056

申请日：2015-07-28

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Nicholas PAPADOPOULOS ,  Anthony DORE ,  Douglas MACDONALD

IPC: G01N33/74 ,  C07K14/71 ,  C07K16/22

CPC classification number: G01N33/74 ,  C07K14/71 ,  C07K16/22 ,  C07K2319/30 ,  G01N2333/515 ,  G01N2800/52

Abstract: The invention provides a method for enriching the level of VEGF-A121 isoform in a sample by selectively removing the VEGF-A165 isoform from the sample using a neuropilin-1 pull-down procedure, then determining the total amount of VEGF-A remaining afterward. The invention provides methods of treating a patient suffering from a disease which may benefit from the administration of a VEGF antagonist by determining the level or ratio of VEGF-A121 in the patient's circulation. Methods of diagnosis, prognosis, monitoring, and patient stratification are also provided.

Abstract translation: 本发明提供了通过使用神经丝氨酸-1下拉法从样品中选择性除去VEGF-A165同种型，然后确定其后剩余的VEGF-A的总量，从而提高样品中VEGF-A121同种型水平的方法。 本发明提供了通过确定患者循环中VEGF-A121的水平或比例来治疗患有可能受益于VEGF拮抗剂的患者的患者的方法。 还提供了诊断，预后，监测和患者分层的方法。

公开(公告)号：US20160304615A1

公开(公告)日：2016-10-20

申请号：US15170628

申请日：2016-06-01

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Jessica R. KIRSHNER ,  Douglas MACDONALD ,  Gavin THURSTON ,  Joel H. MARTIN ,  Frank DELFINO ,  Thomas NITTOLI ,  Marcus KELLY

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30 ,  A61K47/48

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3069 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.

公开(公告)号：US20150259423A1

公开(公告)日：2015-09-17

申请号：US14643886

申请日：2015-03-10

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Jessica R. KIRSHNER ,  Douglas MACDONALD ,  Gavin THURSTON ,  Joel H. MARTIN ,  Frank DELFINO ,  Thomas NITTOLI ,  Marcus KELLY

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K47/48

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3069 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.

Abstract translation: 本发明提供了结合EGFR（EGFRvIII）的III类变体的抗体及其使用方法。 根据某些实施方案，本发明的抗体以高亲和力结合人EGFRvIII。 本发明的抗体可以是完全人抗体。 本发明包括与细胞毒性剂，放射性核素或对细胞生长或增殖有害的其它部分缀合的抗EGFRvIII抗体。 本发明的抗体可用于治疗各种癌症。

公开(公告)号：US20250154286A1

公开(公告)日：2025-05-15

申请号：US19025495

申请日：2025-01-16

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Mark W. SLEEMAN ,  Joel H. MARTIN ,  Tammy T. HUANG ,  Douglas MACDONALD

IPC: C07K16/40 ,  A61K39/00 ,  A61K39/08 ,  C07K16/12 ,  C12N15/09 ,  G01N33/569

Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

公开(公告)号：US20150284474A1

公开(公告)日：2015-10-08

申请号：US14737488

申请日：2015-06-12

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Mark W. SLEEMAN ,  Joel H. MARTIN ,  Tammy T. HUANG ,  Douglas MACDONALD

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12Y304/21061

Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

Abstract translation: 特异性结合并抑制人前体蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（hPCSK9）的人抗体的人抗体或抗原结合片段，其特征在于能够在24,60或90天将血清LDL胆固醇降低40-80％ 相对于前期水平，血清HDL胆固醇几乎没有或没有降低和/或通过ALT和AST测量确定对肝功能具有很小或没有可测量的影响。

公开(公告)号：US20130315907A1

公开(公告)日：2013-11-28

申请号：US13900129

申请日：2013-05-22

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Nicholas PAPADOPOULOS ,  Anthony DORE ,  Douglas MACDONALD

IPC: G01N33/74

CPC classification number: G01N33/74 ,  C07K14/71 ,  C07K16/22 ,  C07K2319/30 ,  G01N2333/515 ,  G01N2800/52

Abstract: The invention provides a method for determining the level of VEGF-A121 isoform in a sample by selectively removing the VEGF-A165 isoform from the sample using a neuropilin-1 pull-down procedure, then determining the total amount of VEGF-A remaining afterward. The invention provides methods of treating a patient suffering from a disease which may benefit from the administration of a VEGF antagonist by determining the level of VEGF-A121 in the patient's circulation. Methods of diagnosis, prognosis, monitoring, and patient stratification are also provided.

Abstract translation: 本发明提供了一种通过使用神经丝氨酸-1下拉法从样品中选择性除去VEGF-A165同种型，然后测定其后剩余的VEGF-A总量来确定样品中VEGF-A121同种型水平的方法。 本发明提供了通过测定患者血液循环中VEGF-A121的水平来治疗患有可能受益于VEGF拮抗剂的疾病的患者的方法。 还提供了诊断，预后，监测和患者分层的方法。

公开(公告)号：US20230340153A1

公开(公告)日：2023-10-26

申请号：US18296265

申请日：2023-04-05

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Mark W. SLEEMAN ,  Joel H. MARTIN ,  Tammy T. HUANG ,  Douglas MACDONALD

IPC: C07K16/40 ,  A61K39/08 ,  G01N33/569 ,  C12N15/09 ,  C07K16/12

CPC classification number: C07K16/40 ,  A61K39/08 ,  G01N33/56911 ,  C12N15/09 ,  C12Y304/21061 ,  C07K16/1282 ,  A61K2039/505

Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.